Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Market Cap & Net Worth: Regenerx Biopharm In (RGRX)
Regenerx Biopharm In (OTCQB:RGRX) has a market capitalization of $2.10K ($2.10K) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #49019 globally and #15038 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Regenerx Biopharm In's stock price $0.00 by its total outstanding shares 1496966 (1.50 Million).
Regenerx Biopharm In Market Cap History: 2015 to 2025
Regenerx Biopharm In's market capitalization history from 2015 to 2025. Data shows change from $658.67K to $2.10K (-44.90% CAGR).
Regenerx Biopharm In Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Regenerx Biopharm In's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.71x
Regenerx Biopharm In's market cap is 2.71 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $658.67K | $60.61K | -$5.27 Million | 10.87x | N/A |
| 2016 | $474.99K | $93.31K | $229.12K | 5.09x | 2.07x |
| 2017 | $254.48K | $56.65K | $286.49K | 4.49x | 0.89x |
| 2018 | $232.03K | $69.67K | -$1.99 Million | 3.33x | N/A |
| 2019 | $209.58K | $76.76K | -$1.40 Million | 2.73x | N/A |
| 2020 | $666.15K | $76.76K | -$1.52 Million | 8.68x | N/A |
| 2021 | $239.51K | $76.76K | -$1.60 Million | 3.12x | N/A |
| 2022 | $207.93K | $76.76K | -$1.73 Million | 2.71x | N/A |
Competitor Companies of RGRX by Market Capitalization
Companies near Regenerx Biopharm In in the global market cap rankings as of March 18, 2026.
Key companies related to Regenerx Biopharm In by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Regenerx Biopharm In Historical Marketcap From 2015 to 2025
Between 2015 and today, Regenerx Biopharm In's market cap moved from $658.67K to $ 2.10K, with a yearly change of -44.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.10K | 0.00% |
| 2024 | $2.10K | +16.67% |
| 2023 | $1.80K | -99.14% |
| 2022 | $207.93K | -13.19% |
| 2021 | $239.51K | -64.04% |
| 2020 | $666.15K | +217.86% |
| 2019 | $209.58K | -9.68% |
| 2018 | $232.03K | -8.82% |
| 2017 | $254.48K | -46.42% |
| 2016 | $474.99K | -27.89% |
| 2015 | $658.67K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Regenerx Biopharm In was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.10K USD |
| MoneyControl | $2.10K USD |
| MarketWatch | $2.10K USD |
| marketcap.company | $2.10K USD |
| Reuters | $2.10K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.